Atypical Teratoid Rhabdoid Tumor (ATRT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Atypical Teratoid Rhabdoid Tumor (ATRT) is a rare and aggressive type of embryonal tumor of the central nervous system (CNS) occurring in childhood, primarily occurring at age of fewer than 3 years. ATRTs are associated with a very poor prognosis, with a reported median survival of 6–12months in most pediatric cases. ATRTs demonstrate pathological findings that are typical of primitive neuroectodermal tumors (PNET), featuring necrosis with a high rate of mitotic activity and the presence of rhabdoid cells. The majority of AT-RTs also demonstrate a loss of INI-1 nuclear staining, ATRTs can form anywhere in the CNS spread to the spinal cord. ATRTs can form outside the CNS, such as in the kidney. ATRTs develop from several different very young cells called embryonal cells. These cells include rhabdoid, neuroepithelial, epithelial, and mesenchymal. Due to the extremely rare incidence of this tumor in adult populations, diagnosis is often delayed given that it falls much lower on the differential diagnosis compared to other more common tumors.
·
Yearly around 60 to 75 patients are being
diagnosed with Atypical Teratoid Rhabdoid Tumor (ATRT) in the USA with a low
5-year survival of ~30%.
Thelansis’s “Atypical Teratoid
Rhabdoid Tumor (ATRT) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Atypical
Teratoid Rhabdoid Tumor (ATRT) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights
of Atypical Teratoid Rhabdoid Tumor (ATRT) across 8 MM market from the centre
of Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Atypical Teratoid Rhabdoid Tumor
(ATRT) Market
Forecast Patient Based Forecast Model (MS. Excel Based Automated
Dashboard), which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
-1.jpg)
Comments
Post a Comment